Cases & Deals

  • Home
  • Practices
  • REGENXBIO resolves patent dispute with Aldevron over patented host cells used in gene therapy applications

Share

REGENXBIO resolves patent dispute with Aldevron over patented host cells used in gene therapy applications

December 2022

Client(s) REGENXBIO Inc.

Jones Day represented plaintiff REGENXBIO Inc. in a patent infringement case brought against Aldevron LLC claiming that without authorization, Aldevron used and manufactured cultured host cells containing recombinant nucleic acid molecules with sequences encoding AAV8 capsid protein(s) and a heterologous non-AAV sequence. These cultured host cells are used to replicate plasmid DNA used to make capsid proteins to package genes for gene therapy applications. The case was successfully resolved.

REGENXBIO Inc., et al. v. Aldevron LLC, No. 3-20-cv-00171 (D.N.D.)

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.